Trailing-twelve-month (TTM) revenue is $31.27 Million with a year-over-year growth of (25.68%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $8,292,362 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $13,678,651 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09 |
| Q1 FY2026Period ended 2026-03-31 | $9,131,317 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $166,458 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $31,268,788 |
Current P/S: $106,979,334 market capitalization ÷ $31,268,788 TTM revenue = 3.42x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $166458.00.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:36:21.412Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Acetadote | $2M | $850,993 | $501,040 | N/A | N/A | N/A |
| Caldolor | $5M | $5M | $5M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Non-US | $2M | $2M | $2M | $1M | $3M | $5M |
$31.27M
$31.27 Million
(25.68%)
vs. $42.07M a year ago (TTM)
+3.53%
5 Year compound annual growth rate
1 Year
(25.68%)
3 Year
(8.37%)
5 Year
+3.53%
10 Year
+0.06%
15 Year
(3.09%)
20 Year
+7.39%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $44.52M | +$6.65M | +17.57% |
| 2024 | $37.87M | ($1.68M) | (4.26%) |
| 2023 | $39.55M | ($2.46M) | (5.85%) |
| 2022 | $42.01M | +$6.03M | +16.75% |
| 2021 | $35.99M | ($1.46M) | (3.89%) |
| 2020 |
TTM Growth
(25.68%)
3-Year CAGR
(8.37%)
5-Year CAGR
+3.53%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T21:36:21.412Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| Kristalose | $16M | $16M | $15M | N/A | N/A | N/A |
|---|
| Manufactured Product, Other | N/A | N/A | N/A | $2M | $1M | N/A |
|---|
| Omeclamox-Pak | $257,088 | -$388,657 | N/A | N/A | N/A | N/A |
|---|
| Product | N/A | N/A | N/A | $38M | $37M | $40M |
|---|
| Product - Other | N/A | N/A | N/A | N/A | N/A | $4M |
|---|
| Product - Vibativ | N/A | N/A | N/A | N/A | N/A | $9M |
|---|
| Product, Vibativ | $11M | $12M | $7M | N/A | N/A | N/A |
|---|
| RediTrex | $856,657 | $55,321 | -$126,726 | N/A | N/A | N/A |
|---|
| Sancuso | N/A | N/A | $13M | N/A | N/A | N/A |
|---|
| Vaprisol | $1M | $2M | -$447,697 | N/A | N/A | N/A |
|---|
| $37.44M |
| +$3.05M |
| +8.88% |
| 2019 | $34.39M | ($6.35M) | (15.59%) |
| 2018 | $40.74M | ($408,366) | (0.99%) |
| 2017 | $41.15M | +$8.12M | +24.60% |
| 2016 | $33.03M | ($493,491) | (1.47%) |
